Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2.
Sweis, R.F., Wang, Z., Algire, M., Arrowsmith, C.H., Brown, P.J., Chiang, G.G., Guo, J., Jakob, C.G., Kennedy, S., Li, F., Maag, D., Shaw, B., Soni, N.B., Vedadi, M., Pappano, W.N.(2015) ACS Med Chem Lett 6: 695-700
- PubMed: 26101576
- DOI: https://doi.org/10.1021/acsmedchemlett.5b00124
- Primary Citation of Related Structures:
4YND - PubMed Abstract:
A lack of useful small molecule tools has precluded thorough interrogation of the biological function of SMYD2, a lysine methyltransferase with known tumor-suppressor substrates. Systematic exploration of the structure-activity relationships of a previously known benzoxazinone compound led to the synthesis of A-893, a potent and selective SMYD2 inhibitor (IC50: 2.8 nM). A cocrystal structure reveals the origin of enhanced potency, and effective suppression of p53K370 methylation is observed in a lung carcinoma (A549) cell line.
Organizational Affiliation:
Discovery Research, AbbVie, Inc. , 1 North Waukegan Road, North Chicago, Illinois 60064, United States.